Ref. No: FOI0010 Date: 05/07/23

Subject: Treatment for Myelofibrosis

REQUEST & RESPONSE

This request is for STHK ONLY

I have a freedom of information query regarding the treatment for Myelofibrosis. Could you please answer the following questions:

Q1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?

Yes our Trust does treat myeloproliferative neoplasms

Q2. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

The cancer information team does not record data on patients with these diagnosis codes. This is in line with national cancer data collection guidelines.

Q3. How many patients were treated in the past 6 months (for any disease) with:

- Ruxolitinib
- Fedratinib

Drug	No. of Patients
Ruxolitinib	6
Fedratinib	0

- Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:
 - Polycythaemia Vera (ICD10 code D45)
 - Myelofibrosis (ICD10 code D47.4)

The cancer information team does not record data on patients with these diagnosis codes. This is in line with national cancer data collection guidelines.

Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?
- Of these patients, how many have received no active treatment in the past 6 months?

The cancer information team does not record data on patients with these diagnosis codes. This is in line with national cancer data collection guidelines.

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

The Research Department do not participate in any trials for the treatment of myelofibrosis.